Pantothenate derivatives for the treatment of neurologic disorders
The present disclosure relates to pantothenate derivatives for the treatment of neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment of neurologic disorders.
1. A pharmaceutical composition comprising (a) a compound of formula:
or a pharmaceutically acceptable salt thereof, wherein R, R′, and R″ are methyl; and (b) a pharmaceutically acceptable excipient.
2. A pharmaceutical composition comprising (a) a compound of formula:
or a pharmaceutically acceptable salt thereof, wherein R is methyl, R′ is methyl, ethyl, methylcyclopropyl, or benzyl, and R″ is methyl, ethyl, methylcyclopropyl, or benzyl; and (b) a pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 2 , wherein R′ is methyl.
4. The pharmaceutical composition of claim 2 , wherein R′ is ethyl.
5. The pharmaceutical composition of claim 2 , wherein R′ is methylcyclopropyl.
6. The pharmaceutical composition of claim 2 , wherein R′ is benzyl.
7. The pharmaceutical composition of claim 2 , wherein R″ is methyl.
8. The pharmaceutical composition of claim 2 , wherein R″ is ethyl.
9. The pharmaceutical composition of claim 2 , wherein R″ is methylcyclopropyl.
10. The pharmaceutical composition of claim 2 , wherein R″ is benzyl.
11. The pharmaceutical composition of claim 3 , wherein R″ is ethyl.
12. The pharmaceutical composition of claim 3 , wherein R″ is methylcyclopropyl.
13. The pharmaceutical composition of claim 3 , wherein R″ is benzyl.
14. The pharmaceutical composition of claim 7 , wherein R′ is ethyl.
15. The pharmaceutical composition of claim 7 , wherein R′ is methylcyclopropyl.
16. The pharmaceutical composition of claim 7 , wherein R′ is benzyl.